NICTUR
Gp Pharm, S.a.
Application Filed: 2017-11-10
Trademark Application Details
REGISTERED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79228430 |
| Registration Number | 5663531 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Domestic Representative | Elizabeth Lee |
| Attorney Name | Elizabeth Lee |
| Attorney Docket Number | CLM-1161-TM |
| Law Office Assigned | L80 |
| Employee Name | DAWE III, WILLIAM H |
Timeline
| 2017-11-10 | Application Filed |
| 2018-11-13 | Published for Opposition |
| 2019-01-29 | Location: PUBLICATION AND ISSUE SECTION |
| 2019-01-29 | Status: Live/Registered |
| 2019-01-29 | Trademark Registered |
| 2019-06-07 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  GP PHARM, S.A. |
| Address | PolÃgono Industrial Els Vinyets - Els Fogars, Ctra. Comarcal 244, Km 22 SantQuinti de Medi ES E-08777 |
| Legal Entity Type | |
| Legal Entity State | ES |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations for human use for treating nighttime or daytime enuresis, primary nocturnal enuresis, nocturia, Von Willebrand-Jurgens disease, hemorrhaging, bleeding in patients with Hemophilia A, postoperative bleeding and diabetes insipidus, for the management of surgical hemostasis, for use in renal concentrating capacity test, for use in oncology, for treating cancer, for treating cardiovascular diseases, for use as antivirals, for treating inflammatory diseases and disorders of the intestine, for treating inflammatory diseases and disorders of the connective tissue, for treating arthritis, for treating urological diseases and disorders, for treating hormonal diseases and disorders, for treating endocrinological diseases and disorders, for treating psychiatric diseases and disorders, in particular mood disorders, anxiety disorders, cognitive disorders and schizophrenia, for treating neurological and neurodegenerative diseases and disorders, in particular, dementia linked to Alzheimer's disease, Huntington's disease, Parkinson's disease, cerebral palsy, brain injuries and diseases, injuries and diseases of the spinal cord, convulsive disorders, epilepsy, encephalitis, disorders of the central nervous system, ocular motility disorders, dystonia, blepharospasm, strabismus, facial scoliosis and tics, cerebral ischemia, dementia, amyotrophic sclerosis, and lateral multiple sclerosis, for treating auto-immune diseases and disorders, for treating transplant rejection, for treating ophthalmological diseases and disorders such as proliferative or non-proliferative diabetic retinopathy, macular degeneration, age-related macular degeneration, retinal neovascularization, neovascularization associated with choroidal melanoma, retinopathy, central retinal vein occlusion, pigmentary retinitis, uveitis, macular edema and cystoid macular edema; synthetic peptides for the treatment of urological, endocrine and blood diseases and disorders |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | 2018-03-08 | 1 SDRC M: |
| LIMITATION FROM ORIGINAL APPLICATION ENTERED | 2018-03-09 | 2 LIMI I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-03-12 | 3 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2018-03-12 | 4 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2018-03-13 | 5 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2018-03-14 | 6 RFCR E:E-Mail |
| APPLICATION FILING RECEIPT MAILED | 2018-03-16 | 7 MAFR O:Outgoing Correspondence |
| REFUSAL PROCESSED BY MPU | 2018-03-20 | 8 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2018-03-20 | 9 RFCS P: |
| REFUSAL PROCESSED BY IB | 2018-04-13 | 10 RFNT P: |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2018-09-19 | 11 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2018-09-19 | 12 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2018-09-20 | 13 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2018-09-24 | 14 CNSA O:Outgoing Correspondence |
| NOTICE OF PUBLICATION | 2018-10-24 | 15 NPUB O:Outgoing Correspondence |
| NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | 2018-10-24 | 16 OP2R P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2018-10-24 | 17 OPNS P: |
| PUBLISHED FOR OPPOSITION | 2018-11-13 | 18 PUBO A:Allowance for Publication |
| NOTIFICATION PROCESSED BY IB | 2018-11-23 | 19 GPNX P: |
| REGISTERED-PRINCIPAL REGISTER | 2019-01-29 | 20 R.PR A:Allowance for Publication |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2019-04-25 | 21 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2019-04-25 | 22 ARAA I:Incoming Correspondence |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2019-04-29 | 23 FICR P: |
| FINAL DISPOSITION PROCESSED | 2019-05-21 | 24 FIMP P: |
| FINAL DISPOSITION NOTICE SENT TO IB | 2019-05-22 | 25 FICS P: |
| FINAL DECISION TRANSACTION PROCESSED BY IB | 2019-06-07 | 26 FINO P: |
| INTERNATIONAL REGISTRATION RENEWED | 2020-10-19 | 27 RNWL P: |
| COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | 2024-01-29 | 28 REM3 E:E-Mail |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 NICTUR 79228430 5663531 Live/Registered |
GP PHARM, S.A. 2017-11-10 |
 NICTUR 79088593 3964633 Dead/Cancelled |
GP PHARM, S.A. 2010-09-29 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 